Multi-omics liquid biopsy for leptomeningeal metastases in lung cancer: from molecular mechanisms to precision diagnosis and treatment.
Lung cancer remains the leading cause of cancer-related deaths worldwide. This review summarizes recent advances in liquid biopsy biomarkers including ctDNA, DNA methylation, microRNA (miRNA), proteins, and circulating tumor cells (CTCs), focusing on their applications in the diagnosis, treatment monitoring, and prognostic assessment of lung cancer-associated LM, and provides a comparative discussion of liquid biopsy based on plasma and cerebrospinal fluid specimens.
Lung cancer remains the leading cause of cancer-related deaths worldwide. This review summarizes recent advances in liquid biopsy biomarkers including ctDNA, DNA methylation, microRNA (miRNA), proteins, and circulating tumor cells (CTCs), focusing on their applications in the diagnosis, treatment monitoring, and prognostic assessment of lung cancer-associated LM, and provides a comparative discussion of liquid biopsy based on plasma and cerebrospinal fluid specimens.
What the study was
- Study design
- Observational cohort study
- Population
- Human participants; details are provided in the abstract.
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Lung cancer (Amsterdam, Netherlands)
Why it surfaced
Retained as a 8/10 high-priority candidate for Early cancer detection (liquid biopsy, ctDNA, cfDNA); PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.